KRYSTAL BIOTECH INC (KRYS) Fundamental Analysis & Valuation

NASDAQ:KRYS • US5011471027

Current stock price

245.39 USD
-6.01 (-2.39%)
At close:
245.39 USD
0 (0%)
After Hours:

This KRYS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. KRYS Profitability Analysis

1.1 Basic Checks

  • KRYS had positive earnings in the past year.
  • KRYS had a positive operating cash flow in the past year.
  • In multiple years KRYS reported negative net income over the last 5 years.
  • In multiple years KRYS reported negative operating cash flow during the last 5 years.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • KRYS's Return On Assets of 15.36% is amongst the best of the industry. KRYS outperforms 95.38% of its industry peers.
  • KRYS has a better Return On Equity (16.80%) than 94.41% of its industry peers.
  • KRYS's Return On Invested Capital of 10.34% is amongst the best of the industry. KRYS outperforms 93.83% of its industry peers.
Industry RankSector Rank
ROA 15.36%
ROE 16.8%
ROIC 10.34%
ROA(3y)8.38%
ROA(5y)-2.21%
ROE(3y)9.21%
ROE(5y)-2.18%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • KRYS has a Profit Margin of 52.64%. This is amongst the best in the industry. KRYS outperforms 98.07% of its industry peers.
  • KRYS has a Operating Margin of 41.41%. This is amongst the best in the industry. KRYS outperforms 98.46% of its industry peers.
  • With an excellent Gross Margin value of 94.08%, KRYS belongs to the best of the industry, outperforming 94.80% of the companies in the same industry.
Industry RankSector Rank
OM 41.41%
PM (TTM) 52.64%
GM 94.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. KRYS Health Analysis

2.1 Basic Checks

  • KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, KRYS has more shares outstanding
  • Compared to 5 years ago, KRYS has more shares outstanding
  • There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 40.14 indicates that KRYS is not in any danger for bankruptcy at the moment.
  • KRYS has a better Altman-Z score (40.14) than 94.61% of its industry peers.
  • KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 40.14
ROIC/WACC1.11
WACC9.35%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 9.95 indicates that KRYS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 9.95, KRYS is doing good in the industry, outperforming 79.58% of the companies in the same industry.
  • KRYS has a Quick Ratio of 9.56. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
  • KRYS has a Quick ratio of 9.56. This is in the better half of the industry: KRYS outperforms 79.19% of its industry peers.
Industry RankSector Rank
Current Ratio 9.95
Quick Ratio 9.56
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. KRYS Growth Analysis

3.1 Past

  • KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.10%, which is quite impressive.
  • The Revenue has grown by 33.95% in the past year. This is a very strong growth!
EPS 1Y (TTM)129.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.84%
Revenue 1Y (TTM)33.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.52%

3.2 Future

  • Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.22% on average per year.
  • The Revenue is expected to grow by 30.47% on average over the next years. This is a very strong growth
EPS Next Y14.92%
EPS Next 2Y27.47%
EPS Next 3Y30.26%
EPS Next 5Y36.22%
Revenue Next Year38.65%
Revenue Next 2Y36.89%
Revenue Next 3Y34.98%
Revenue Next 5Y30.47%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

5

4. KRYS Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 35.82, KRYS can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, KRYS is valued cheaper than 91.33% of the companies in the same industry.
  • KRYS is valuated rather expensively when we compare the Price/Earnings ratio to 24.88, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 31.17, KRYS can be considered very expensive at the moment.
  • 91.91% of the companies in the same industry are more expensive than KRYS, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, KRYS is valued a bit more expensive.
Industry RankSector Rank
PE 35.82
Fwd PE 31.17
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaply inside the industry as 90.94% of the companies are valued more expensively.
  • 92.87% of the companies in the same industry are more expensive than KRYS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 37.97
EV/EBITDA 37.09
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of KRYS may justify a higher PE ratio.
  • A more expensive valuation may be justified as KRYS's earnings are expected to grow with 30.26% in the coming years.
PEG (NY)2.4
PEG (5Y)N/A
EPS Next 2Y27.47%
EPS Next 3Y30.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KRYS Dividend Analysis

5.1 Amount

  • KRYS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KRYS Fundamentals: All Metrics, Ratios and Statistics

KRYSTAL BIOTECH INC

NASDAQ:KRYS (3/27/2026, 8:00:03 PM)

After market: 245.39 0 (0%)

245.39

-6.01 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners97.07%
Inst Owner Change-0.74%
Ins Owners11.55%
Ins Owner Change-1.67%
Market Cap7.17B
Revenue(TTM)389.13M
Net Income(TTM)204.83M
Analysts87.06
Price Target313.24 (27.65%)
Short Float %11.74%
Short Ratio9.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)79.28%
Min EPS beat(2)18.32%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)39.2%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)11.67%
EPS beat(12)5
Avg EPS beat(12)3.31%
EPS beat(16)8
Avg EPS beat(16)3.37%
Revenue beat(2)1
Avg Revenue beat(2)1.29%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)3
Avg Revenue beat(8)-1.04%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.6%
PT rev (3m)38.05%
EPS NQ rev (1m)-11.45%
EPS NQ rev (3m)-8.14%
EPS NY rev (1m)-5.48%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)-4.39%
Revenue NQ rev (3m)-4.54%
Revenue NY rev (1m)-2.51%
Revenue NY rev (3m)-2.25%
Valuation
Industry RankSector Rank
PE 35.82
Fwd PE 31.17
P/S 18.43
P/FCF 37.97
P/OCF 35.71
P/B 5.88
P/tB 5.88
EV/EBITDA 37.09
EPS(TTM)6.85
EY2.79%
EPS(NY)7.87
Fwd EY3.21%
FCF(TTM)6.46
FCFY2.63%
OCF(TTM)6.87
OCFY2.8%
SpS13.31
BVpS41.72
TBVpS41.72
PEG (NY)2.4
PEG (5Y)N/A
Graham Number80.19
Profitability
Industry RankSector Rank
ROA 15.36%
ROE 16.8%
ROCE 13.09%
ROIC 10.34%
ROICexc 31.58%
ROICexgc 31.58%
OM 41.41%
PM (TTM) 52.64%
GM 94.08%
FCFM 48.55%
ROA(3y)8.38%
ROA(5y)-2.21%
ROE(3y)9.21%
ROE(5y)-2.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 208.79%
Cap/Sales 3.07%
Interest Coverage 250
Cash Conversion 120.39%
Profit Quality 92.23%
Current Ratio 9.95
Quick Ratio 9.56
Altman-Z 40.14
F-Score7
WACC9.35%
ROIC/WACC1.11
Cap/Depr(3y)171.82%
Cap/Depr(5y)857.51%
Cap/Sales(3y)9.27%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.84%
EPS Next Y14.92%
EPS Next 2Y27.47%
EPS Next 3Y30.26%
EPS Next 5Y36.22%
Revenue 1Y (TTM)33.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.52%
Revenue Next Year38.65%
Revenue Next 2Y36.89%
Revenue Next 3Y34.98%
Revenue Next 5Y30.47%
EBIT growth 1Y56.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.89%
EBIT Next 3Y57.38%
EBIT Next 5YN/A
FCF growth 1Y58.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.75%
OCF growth 3YN/A
OCF growth 5YN/A

KRYSTAL BIOTECH INC / KRYS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?

ChartMill assigns a fundamental rating of 6 / 10 to KRYS.


What is the valuation status for KRYS stock?

ChartMill assigns a valuation rating of 5 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Fairly Valued.


What is the profitability of KRYS stock?

KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for KRYS stock?

The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 35.82 and the Price/Book (PB) ratio is 5.88.


What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?

The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 8 / 10.